ARWRNASDAQ

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. · Pasadena, CA · founded 1989

Arrowhead Pharmaceuticals is a Pasadena, California RNAi biotech with a broad pipeline of small interfering RNA (siRNA) drugs delivered to specific tissues using its TRiM targeted-delivery platform. Programs span cardiometabolic disease (cholesterol-lowering, lipoprotein(a)), pulmonary disorders, and rare conditions, with multiple wholly-owned and partnered (Takeda, Amgen, Janssen) candidates in mid-to-late stage development.

Lead asset: plozasiran · Ph3 · Familial Chylomicronemia; siRNA · APOC3-targeting RNAi
Pipeline: 1 drug · 1 program; 1 Cardio-Renal
Modalities: siRNA×1

FocusCardio-RenalRare DiseaseNASH / MASH

Last refresh · 9d ago · PR

$21.00-3.14%1Y

ARWR · daily close · illustrative · 1 catalyst marked

PDUFA-26%

1Y high$22.971Y low$19.69range$3.28(17%)past catalysts

Peers in this space

same sector or modality · sorted by match strength + market cap

1 programmatch: sector + modality

Cardio-Renaloligonucleotide

1 programmatch: sector

Cardio-Renalsmall molecule

1 programmatch: sector

Cardio-Renalgene therapy

1 programmatch: sector

Pipeline & catalysts

1 drug · 1 programs · 2 upcoming catalysts

Pipeline by phase1programs

Preclin0
Ph10
Ph20
Ph31
Filed0
Approved0

plozasiran

siRNAAPOC3-targeting RNAi

Familial Chylomicronemia

Phase 3

1 program·1 trial·View drug →

Upcoming catalysts2

Conf.MAY 152026·15 daysEXACT

Plozasiran Long-term Open-Label Data — EAS Congress

Long-term open-label plozasiran data at EAS Congress. Supportive readout ahead of the Phase 3 PALISADE topline (Q1 2027). Watch: triglyceride reduction durability, dose-spacing profile.

Cited“Long-term open-label data for plozasiran will be presented at the European Atherosclerosis Society Congress on May 15, 2026.”

Conference Data·PR·disclosed 9d ago·NCT06028386n=110

ReadoutQ1'27·8 monthsQTR

Plozasiran PALISADE Phase 3 FCS Topline

Phase 3 efficacy readout for Arrowhead’s wholly-owned plozasiran (APOC3 siRNA) in familial chylomicronemia syndrome (FCS). Same indication: Ionis’s olezarsen (PDUFA 2026-12-19). Watch: triglyceride reduction at month 12, acute pancreatitis events.

Cited“PALISADE, the Phase 3 study of plozasiran in familial chylomicronemia syndrome, is expected to deliver topline data in Q1 2027.”

Topline Readout·PR·disclosed 9d ago·NCT06028386n=110

Past catalyst impact

4 historical events · % change vs announcement

DateKindEventOutcome+1W+1M+6M

Jun 29, 2025PDUFAplozasiran — PDUFA — CRL IssuedNegative-26.1%-21.0%-18.0%

Mar 1, 2025AdComplozasiran — Advisory Committee — 12–2 Vote in FavorPositive+19.5%+15.9%+18.8%

Mar 1, 2025PDUFAplozasiran — PDUFA — ApprovedNegative-41.8%-35.9%-46.4%

Sep 2, 2024Readoutplozasiran — Phase 3 Topline — Mixed ResultNegative-16.7%-26.2%-42.7%

% change vs ticker close on the announcement date · backtest illustrative

Smart money

Insider activity

SEC EDGAR Form 4 · last 90 days

Insider activity · last 90 days

Form 4 trail · 4 transactions · 4 insiders

1 near a catalyst

Net flow

−$380.9K

Buys

$470.9K

1 txns

Sells

$851.8K

3 txns

Largest

−$552.6K

Director sell

Net flow per quarter · last 8Q

12 txns · sum −$13.65M

24Q324Q425Q125Q225Q325Q426Q126Q2

buys · $2.20Msells · $15.85M

Insider · roleActionSharesPriceValueDate

R. Iyer

Chair

Sell3,155$25.13−$79.3K

Apr 9, 2026

36d to catalyst

B. Singh

Director

Buy20,565$22.90+$470.9K

Mar 12, 2026

N. Greene

Director

Sell25,678$21.52−$552.6K

Mar 6, 2026

J. Singh

EVP

Sell9,403$23.39−$220.0K

Jan 30, 2026

Congressional trading

STOCK Act PTRs · House & Senate

Congressional trading · STOCK Act · last 365d

3 trades · 3 members

1 near a catalyst

Est. net flow

+$3.38M

midpoint · brackets only

Buys

Sells

Party mix

3 D0 R

Member · chamberActionBracket~ midpointOwnerDate · disclosure

Sen. C. Walsh

Senate · NY

Buy$1.00M–$5.00M~$3.00Mself

Mar 1, 2026

filed +18d

75d to catalyst

Sen. E. Mendoza

Senate · AZ

Sell$250K–$500K~$375Kself

Aug 6, 2025

filed +38d

Sen. A. Reyes

Senate · CA

Buy$500K–$1.00M~$750Kdependent

May 24, 2025

filed +35d

Source: Senate eFD & House Clerk PTR feeds · members must disclose within 45 days · midpoints reflect bracket midpoint, not actual transaction value

Top ETF holders

ETF NAV disclosures · 13F filings

ETF holders · NAV disclosures

2 ETFs hold the position

Held by ETFs

$18.7M

aggregate position

Of market cap

0.85%

aggregate ETF share

Top holder

IBB0.22%

iShares Biotechnology ETF

TickerETF · familyThemeNAV% of NAVPosition

IBB

iShares Biotechnology ETF

iShares

Broad biotech$8.40B0.22%$18.5M

PBE

Invesco Dynamic Biotechnology

Invesco

Broad biotech$175.0M0.11%$193K

Source: ETF NAV disclosures + quarterly 13F filings · narrow-theme ETFs disclose holdings daily; broad ETFs quarterly · % of NAV is the position weight inside the fund

KOL network

CMS OpenPayments · 2024 – 2025

KOL network · CMS OpenPayments

17 physicians paid · 89 disclosed records

Total 2025+2024

$5.84M

YoY

+46%

Research Grant$2.12MCo-Investigator$1.71MEquity / Ownership$1.47MConsulting$312.4KSpeaking$188.4KTravel & Lodging$40.3KFood & Beverage$2.5K

Physician · affiliationSpecialtyTop categoryTotalRecords

Dr. Lin Chen

Mayo Clinic

Heart FailureResearch Grant$657.7K7

Dr. Anita Nakamura

NYU Langone

Heart FailureCo-Investigator$611.0K4

Dr. Yuki Mendoza

Cleveland Clinic

Heart FailureCo-Investigator$489.7K6

Dr. Lin Kowalski

University of Michigan

CardiologyCo-Investigator$451.2K7

Dr. Yuki Fischer

Cedars-Sinai

Heart FailureResearch Grant$441.6K4

Dr. Anita Andersson

Cleveland Clinic

Interventional CardiologyResearch Grant$425.1K5

Dr. Olivia Murphy

Yale Medical

CardiologyCo-Investigator$412.2K4

Dr. Sarah Reyes

Johns Hopkins

CardiologyEquity / Ownership$393.9K5

Dr. James Mendoza

Yale Medical

Heart FailureResearch Grant$390.4K7

Dr. Daniel Fischer

Cleveland Clinic

Interventional CardiologyCo-Investigator$332.8K7

Source: CMS OpenPayments · quarterly drops · physicians identified by NPI · aggregated across all programs

Government & IP

Federal lobbying

Senate LDA disclosures · last 8 quarters

Federal lobbying · LDA · last 8 quarters

$255K disclosed · 3 firms engaged

YoY change

+42%

last 4Q vs prior 4Q

24Q3Q425Q1Q2Q3Q426Q1Q2

Top lobbying firms · last 8Q

Cornerstone Government Affairs$109K

7 quarters active

Tiber Creek Group$82K

5 quarters active

Holland & Knight$64K

5 quarters active

Top issues lobbied

Drug Supply Chain Security Act$77K
Sunshine Act expansion$77K
BIOSIM Act / Biosimilars$68K
FDA user fee reauthorization (PDUFA / BsUFA)$32K

Source: Senate LDA database (lda.senate.gov) · quarterly registrant filings · spend is the company-wide total disclosed

Government contracts

USAspending.gov · BARDA · NIH · DoD · HHS · VA

Federal contracts · USAspending.gov

2 awards · 2 agencies

Total awarded

$40.4M

across all programs

Active

$40.4M

option periods incl.

Top agency

NIH / NHLBI$27.8M

largest active: Cardiovascular Outcomes Trial Co-Funding

AgencyTitle · type · award IDStatusValueAwarded → ends

NIH / NHLBI

Cardiovascular Outcomes Trial Co-Funding

Cooperative Agreement · NIH-63482196

active$27.8MNov 2024→ Nov 2027

NIH / NIAID

Vaccine Adjuvant Research — Phase 1 / 2

Grant · NIH-97729890

active$12.5MOct 2024→ Nov 2027

Source: USAspending.gov · SAM.gov · every federal contract / grant / cooperative agreement is public · values are obligated awards (may include option periods)

U.S. Patents

USPTO PEDS & Patent Public Search

U.S. Patents · USPTO

9 granted · 0 pending

Total in portfolio

Granted in last 12mo

Expiring < 2yr

Nearest expiry

Apr 2030

Patent #Title · inventor · drugTypeStatus · filedExpiry

12,000,352

Therapeutic peptide compositions for plozasiran

N. Andersson + 3 · plozasiran

Composition of Matter

grantedfiled Apr 2024

exp. Apr 2044

18.0y left

11,701,679

Combination therapy comprising plozasiran

L. Park + 3 · plozasiran

Method of Use

grantedfiled Apr 2023

exp. Apr 2043

17.0y left

10,514,165

Small molecule modulators of plozasiran

C. Patel + 3 · plozasiran

Composition of Matter

grantedfiled Apr 2015

exp. Apr 2035

9.0y left

11,363,630

Purification methods for plozasiran

A. Goldstein + 4 · plozasiran

Process

grantedfiled Apr 2016

exp. Apr 2036

10.0y left

10,333,733

Sustained-release oral compositions of plozasiran

P. Goldstein · plozasiran

Formulation

grantedfiled Apr 2015

exp. Apr 2035

9.0y left

10,631,571

Methods of stratifying patients for treatment with plozasiran

S. Romano + 2 · plozasiran

Method of Use

grantedfiled Apr 2014

exp. Apr 2034

8.0y left

11,253,917

Scalable cell-line manufacturing for plozasiran

A. Hoffman + 2 · plozasiran

Process

grantedfiled Apr 2011

exp. Apr 2031

5.0y left

11,600,657

Methods of stratifying patients for treatment with plozasiran

T. Hoffman + 4 · plozasiran

Method of Use

grantedfiled Apr 2011

exp. Apr 2031

5.0y left

showing 8 of 9 · full portfolio available on Pro

Source: USPTO PEDS & Patent Public Search · composition-of-matter is the headline asset · expiration = 20 years from filing

News

PR wires · biotech trades · company IR · last 90 days

News · last 90 days

8 items from 4 categories

clinical5earnings1regulatory1corporate1

8d ago

ARWR presents plozasiran data at major medical conference

FierceBiotech·clinical

14d ago

ARWR reports Q4 results, reaffirms 2026 guidance

Business Wire·earnings

1mo ago

ARWR completes enrollment in plozasiran Phase 2 trial

FierceBiotech·clinical

2mo ago

ARWR reports topline results from Phase 2 trial of plozasiran

PR Newswire·clinical

2mo ago

ARWR receives Orphan Drug Designation for plozasiran

Endpoints News$·regulatory

2mo ago

ARWR presents plozasiran data at major medical conference

Endpoints News$·clinical

3mo ago

ARWR announces $308 million private placement

PR Newswire·corporate

3mo ago

ARWR completes enrollment in plozasiran Phase 2 trial

FierceBiotech·clinical

Sources: PR wires + biotech-trade publications + company IR · paywalled outlets ($) link to publisher · we never paraphrase the headline

Financials

snapshot · sourced to filings · refreshed at next 10-Q

Trading

Previous close

$21.00

Open

$20.94

Day Δ

+0.06

+0.29%

Day range

$20.82 – $21.12

52W range

$19.69 – $22.97

Avg daily volume

1.49M

Valuation & ownership

Enterprise value

$1.9B

Shares out

104.76M

Float

93.24M

Insider %

4.96%

Institutional %

59.96%

Beta

1.46

vs SPY · 52w

Balance sheet & burn

Cash + invest

$557M

Total debt

$196M

Debt / equity

3.96

Cash burn / Q

$58M

R&D spend TTM

$238M

43% of cash

ATM available

$462M

dilution risk

Earnings

EPS latest

$-0.21

EPS Δ vs prior

+0.16

EPS estimate

$-0.15

next quarter

EPS prior

$-0.37

Next earnings

Jun 18, 2026

Rev guidance

$46M

All values reflect the most recent 10-Q / 10-K filing or seeded equivalent. Beta, IV, short interest, and borrow availability are derived from broker-feed conventions. Upgrade to Pro for live updates.

Recent disclosure activity

last 2 observations

9d agoplozasiranPlozasiran PALISADE Phase 3 FCS ToplineHighPR

9d agoplozasiranPlozasiran Long-term Open-Label Data — EAS CongressHighPR